214 related articles for article (PubMed ID: 30052267)
1. Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients.
Bao X; Wu J; Kim S; LoRusso P; Li J
J Clin Pharmacol; 2019 Jan; 59(1):20-34. PubMed ID: 30052267
[TBL] [Abstract][Full Text] [Related]
2. Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure.
Tsuboya A; Kubota Y; Ishida H; Ohkuma R; Ishiguro T; Hirasawa Y; Ariizumi H; Tsunoda T; Sasaki Y; Matsumoto N; Kondo Y; Tomoda Y; Kusuhara H; Fujita KI
Cancer Chemother Pharmacol; 2021 Sep; 88(3):543-553. PubMed ID: 34117512
[TBL] [Abstract][Full Text] [Related]
3. Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients.
Karas S; Etheridge AS; Tsakalozou E; Ramírez J; Cecchin E; van Schaik RHN; Toffoli G; Ratain MJ; Mathijssen RHJ; Forrest A; Bies RR; Innocenti F
AAPS J; 2020 Mar; 22(3):59. PubMed ID: 32185579
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
5. Assessment of exposure risk of irinotecan and its active metabolite, SN-38, through perspiration during chemotherapy.
Irie K; Okada A; Masuda Y; Fukushima K; Sugioka N; Okuda C; Hata A; Kaji R; Okada Y; Katakami N; Fukushima S
J Oncol Pharm Pract; 2019 Jun; 25(4):865-868. PubMed ID: 29651916
[TBL] [Abstract][Full Text] [Related]
6. Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
Lei CS; Hou YC; Pai MH; Lin MT; Yeh SL
J Nutr Biochem; 2018 Jan; 51():105-113. PubMed ID: 29125991
[TBL] [Abstract][Full Text] [Related]
7. Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.
Mohammad AS; Griffith JI; Adkins CE; Shah N; Sechrest E; Dolan EL; Terrell-Hall TB; Hendriks BS; Lee H; Lockman PR
Pharm Res; 2018 Jan; 35(2):31. PubMed ID: 29368289
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
Augustine T; Maitra R; Zhang J; Nayak J; Goel S
Invest New Drugs; 2019 Oct; 37(5):948-960. PubMed ID: 30612311
[TBL] [Abstract][Full Text] [Related]
9. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice.
Mallick P; Shah P; Gandhi A; Ghose R
Life Sci; 2015 Oct; 139():132-8. PubMed ID: 26334566
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.
Kciuk M; Marciniak B; Kontek R
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664667
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38.
Iwase M; Fujita KI; Nishimura Y; Seba N; Masuo Y; Ishida H; Kato Y; Kiuchi Y
Cancer Chemother Pharmacol; 2019 May; 83(5):993-998. PubMed ID: 30810774
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
Santos A; Zanetta S; Cresteil T; Deroussent A; Pein F; Raymond E; Vernillet L; Risse ML; Boige V; Gouyette A; Vassal G
Clin Cancer Res; 2000 May; 6(5):2012-20. PubMed ID: 10815927
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Investigation of Irinotecan Metabolism, Transport, and Gut Microbiome Activation.
Parvez MM; Basit A; Jariwala PB; Gáborik Z; Kis E; Heyward S; Redinbo MR; Prasad B
Drug Metab Dispos; 2021 Aug; 49(8):683-693. PubMed ID: 34074730
[TBL] [Abstract][Full Text] [Related]
14. Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting Chemoembolization.
Levy EB; Peer C; Sissung TM; Venkatesan A; Pandalai P; Greten T; Hughes MS; Garcia C; Peretti J; Figg W; Lewis A; Wood B
J Vasc Interv Radiol; 2019 Jan; 30(1):19-22. PubMed ID: 30527657
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Tentori L; Leonetti C; Scarsella M; Muzi A; Mazzon E; Vergati M; Forini O; Lapidus R; Xu W; Dorio AS; Zhang J; Cuzzocrea S; Graziani G
FASEB J; 2006 Aug; 20(10):1709-11. PubMed ID: 16809434
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer.
Oyaga-Iriarte E; Insausti A; Sayar O; Aldaz A
Eur J Clin Pharmacol; 2019 Apr; 75(4):529-542. PubMed ID: 30610273
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives.
Ramesh M; Ahlawat P; Srinivas NR
Biomed Chromatogr; 2010 Jan; 24(1):104-23. PubMed ID: 19852077
[TBL] [Abstract][Full Text] [Related]
18. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
de Man FM; Goey AKL; van Schaik RHN; Mathijssen RHJ; Bins S
Clin Pharmacokinet; 2018 Oct; 57(10):1229-1254. PubMed ID: 29520731
[TBL] [Abstract][Full Text] [Related]
19. SN-38 Conjugated Gold Nanoparticles Activated by Ewing Sarcoma Specific mRNAs Exhibit In Vitro and In Vivo Efficacy.
Naumann JA; Widen JC; Jonart LA; Ebadi M; Tang J; Gordon DJ; Harki DA; Gordon PM
Bioconjug Chem; 2018 Apr; 29(4):1111-1118. PubMed ID: 29412642
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
